Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Clin Cancer Res. 2012 Jul 23;18(17):4743–4752. doi: 10.1158/1078-0432.CCR-12-0707

Table 1.

Clinicopathological and molecular characteristics of patients and tumors by CpG island methylator phenotype (CIMP) status

Characteristic Total CIMP− CIMP+ P *
No. of patients 99 72 (72.7%) 27 (27.3%)
Sex 1.000
 Male 55 (55.6%) 40 (55.6%) 15 (55.6%)
 Female 44 (44.4%) 32 (44.4%) 12 (44.4%)
Age at surgery 0.247
 < 70 64 (64.6%) 49 (68.1%) 15 (55.6%)
 ≥70 35 (35.4%) 23 (31.9%) 12 (44.4%)
Stage 0.067
 I (T1–2 N0 M0) 8 (8.1%) 3 (4.2%) 5 (18.5%)
 II (T3–4 N0 M0) 21 (21.2%) 18 (25.0%) 3 (11.1%)
 III (anyT N1-2 M0) 64 (64.6%) 47 (65.3%) 17 (63.0%)
 IV (anyT anyN M1) 6 (6.1%) 4 (5.6%) 2 (7.4%)
Tumor differentiation 1.000
 Well/moderate 55 (55.6%) 40 (55.6%) 15 (55.6%)
 Poor 44 (44.4%) 32 (44.4%) 12 (44.4%)
Extent of resection 1.000
 R0 87 (87.9%) 63 (87.5%) 24 (88.9%)
 R1/R2 12 (12.1%) 9 (12.5) 3 (11.1%)
Chemotherapy/radiotherapy 0.448
 No 38 (38.4%) 26 (36.1%) 12 (44.4%)
 Yes 61 (61.6%) 46 (63.9%) 15 (55.6%)
MSI status 0.011
 MSS 79 (79.8%) 62 (86.1%) 17 (63.0%)
 MSI 20 (20.2%) 10 (13.9%) 10 (37.0%)
KRAS 0.114
 Wild-type 67 (67.7%) 52 (72.2%) 15 (55.6%)
 Mutated 32 (32.3%) 20 (27.8%) 12 (44.4%)
MLH1 methylation < 0.001
 U 85 (85.9%) 70 (97.2%) 15 (55.6%)
 M 14 (14.1%) 2 (2.8%) 12 (44.4%)

NOTE:

*

CIMP− versus CIMP+, χ2 test unless indicated otherwise;

Fisher’s exact test.

Abbreviations: CIMP, CpG island methylator phenotype; MSS, microsatellite stable; MSI, microsatellite instability; U, unmethylated; M, methylated.